Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis
- PMID: 31536748
- DOI: 10.1016/j.jhep.2019.09.007
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis
Abstract
Background & aims: Cholangiocarcinoma (CCA) carries a poor prognosis, is increasing in incidence and its causes are poorly understood. Although some risk factors are known, they vary globally and collectively account for a minority of cases. The aim of this study was to perform a comprehensive meta-analysis of risk factors for intrahepatic (iCCA) and extrahepatic cholangiocarcinoma (eCCA), from Eastern and Western world studies.
Methods: A literature search of case-control studies was performed to identify potential risk factors for iCCA and eCCA. Pooled odds ratios (ORs) with 95% CIs and heterogeneity were calculated. Funnel plots were used to assess publication bias, and meta-regression was used to select risk factors for comparison between Eastern and Western studies.
Results: A total of 13 risk factors were selected from 25 case-control studies in 7 geographically diverse countries. The strongest risk factors for both iCCA and eCCA were biliary cysts and stones, cirrhosis, hepatitis B and hepatitis C. Choledochal cysts conferred the greatest risk of both iCCA and eCCA with pooled ORs of 26.71 (95% CI 15.80-45.16) and 34.94 (24.36-50.12), respectively. No significant associations were found between hypertension and obesity for either iCCA or eCCA. Comparing Eastern and Western populations, there was a difference for the association of hepatitis B with iCCA (coefficient = -0.15195; 95% CI -0.278 to -0.025; p = 0.022).
Conclusion: This is the most comprehensive meta-analysis of CCA risk factors to date. Some risk factors, such as diabetes, although less strong, are increasing globally and may be contributing to rising rates of this cancer.
Lay summary: Cholangiocarcinoma (CCA) is a cancer arising in the bile ducts inside (intrahepatic CCA) and connected to the liver (extrahepatic CCA). It is a very aggressive cancer: 95% of patients die within 5 years. CCA rates are increasing globally, but the causes of CCA are poorly understood. The few risk factors that are known account for only a minority of cases. In this study, we found that the strongest risk factors for both intrahepatic and extrahepatic CCA are cysts and stones in the bile ducts, cirrhosis, and hepatitis B and C viruses. Some risk factors for CCA, such as diabetes, although less strong, are increasing globally and may be contributing to rising rates of CCA.
Keywords: Cholangiocarcinoma; Meta-analysis; Risk factors.
Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Comment in
-
Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis].J Hepatol. 2020 Jun;72(6):1216. doi: 10.1016/j.jhep.2020.01.022. Epub 2020 Mar 17. J Hepatol. 2020. PMID: 32197800 No abstract available.
-
Reply to: 'Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis]'.J Hepatol. 2020 Jun;72(6):1217. doi: 10.1016/j.jhep.2020.02.029. Epub 2020 Mar 24. J Hepatol. 2020. PMID: 32216990 No abstract available.
-
Challenges in elucidating cholangiocarcinoma etiology.Hepatobiliary Surg Nutr. 2020 Aug;9(4):537-539. doi: 10.21037/hbsn.2020.02.03. Hepatobiliary Surg Nutr. 2020. PMID: 32832513 Free PMC article. No abstract available.
Similar articles
-
Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: Evidence from a systematic review and meta-analysis.Turk J Gastroenterol. 2020 Mar;31(3):246-256. doi: 10.5152/tjg.2020.19056. Turk J Gastroenterol. 2020. PMID: 32343237 Free PMC article.
-
Hepatitis C virus infection and the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma: evidence from a systematic review and meta-analysis of 16 case-control studies.World J Surg Oncol. 2015 Apr 23;13:161. doi: 10.1186/s12957-015-0583-9. World J Surg Oncol. 2015. PMID: 25903488 Free PMC article. Review.
-
New epidemiologic trends in cholangiocarcinoma.Clin Res Hepatol Gastroenterol. 2023 Nov;47(9):102223. doi: 10.1016/j.clinre.2023.102223. Epub 2023 Oct 4. Clin Res Hepatol Gastroenterol. 2023. PMID: 37797807 Review.
-
Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis.BMC Gastroenterol. 2017 Dec 8;17(1):149. doi: 10.1186/s12876-017-0696-4. BMC Gastroenterol. 2017. PMID: 29216833 Free PMC article. Review.
-
Cholangiocarcinoma miscoding in hepatobiliary centres.Eur J Surg Oncol. 2021 Mar;47(3 Pt B):635-639. doi: 10.1016/j.ejso.2020.09.039. Epub 2020 Oct 1. Eur J Surg Oncol. 2021. PMID: 33032867
Cited by
-
Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma.Cancers (Basel). 2024 Apr 26;16(9):1690. doi: 10.3390/cancers16091690. Cancers (Basel). 2024. PMID: 38730642 Free PMC article. Review.
-
The coexistence of myosteatosis and the creatinine/cystatin C ratio are determinants of outcomes in cholangiocarcinoma patients undergoing curative surgery.Front Oncol. 2024 Apr 19;14:1233768. doi: 10.3389/fonc.2024.1233768. eCollection 2024. Front Oncol. 2024. PMID: 38706605 Free PMC article.
-
Clinical Characteristics of Non-B and Non-C Biopsy-Proven Primary Liver Cancers in an HBV- Endemic Area: A Retrospective Study.J Hepatocell Carcinoma. 2024 Apr 24;11:767-774. doi: 10.2147/JHC.S455741. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 38689801 Free PMC article.
-
Protective effect of higher free thyroxine levels within the reference range on biliary tract cancer risk: a multivariable mendelian randomization and mediation analysis.Front Endocrinol (Lausanne). 2024 Apr 15;15:1379607. doi: 10.3389/fendo.2024.1379607. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38686204 Free PMC article.
-
Global, regional, and national burden and trends analysis of gallbladder and biliary tract cancer from 1990 to 2019 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2019.Front Med (Lausanne). 2024 Apr 4;11:1384314. doi: 10.3389/fmed.2024.1384314. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38638933 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical